5 March 2018 - - US-based biopharmaceutical company Cullgen has garnered seed financing of up to USD 15m by Tokyo-based life-science company GNI Group Ltd. (TOKYO:2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology, the company said.
Cullgen's technology focuses on selective degradation of disease-causing proteins, providing scientists with new means to develop novel therapeutic approaches for various diseases.
This new drug discovery platform has the advantage of accelerating new chemical entities (NCEs) into clinical development in a cost and time efficient manner to benefit patients.
Initial drug discovery programs will focus on oncology and expand into areas such as inflammatory and autoimmune diseases.
Privately held Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology.
The company is dedicated to the development of first-in-class NCEs for the treatment of diseases lacking effective therapeutic approaches.
GNI Group focuses on pharmaceutical and medical device businesses with headquarters in Tokyo and subsidiaries in China and the United States.